Faculty at the Center for Transplantation Sciences, Massachusetts General Hospital, presented data at the 2022 American Transplant Congress about Tonix Pharmaceuticals’ (NASDAQ:TNXP) TNX-1500 product candidate in...
Tonix Pharmaceuticals (NASDAQ:TNXP) met its target enrollment of 470 patients in its Phase 3 study of TNX-102 SL for the management of fibromyalgia. TNX-102 SL is a non-opioid analgesic, administered daily at bedtime...
Tonix Pharmaceuticals (NASDAQ:TNXP) enrolled the first patient in its Phase 3 study of TNX-102 SL for the management of fibromyalgia. TNX-102 SL is a non-opioid analgesic, administered daily at bedtime. The trial will...